Related Experiment Videos
[Long term experience with the LifeSite hemodialysis device]
Summary
The LifeSite hemodialysis system offers a viable long-term vascular access solution for patients unable to undergo arteriovenous fistula creation. This central venous access device demonstrates effective dialysis delivery and a low infection rate, proving useful for extended use.
Area of Science:
- Nephrology
- Vascular Access
Context:
- Arteriovenous fistula creation is not possible for all hemodialysis patients.
- Central venous catheters are often used, but long-term efficacy and complication rates vary.
- The LifeSite hemodialysis access system offers an alternative approach.
Purpose:
- To report on the long-term use and efficacy of the LifeSite hemodialysis access system.
- To evaluate blood flow rates, infection rates, and overall device performance.
- To assess the LifeSite system as an alternative for patients without fistula creation options.
Summary:
- The LifeSite system, a central venous catheter with a titanium alloy valve, was used in six patients for long-term hemodialysis.
- Excellent blood flow (300-345 ml/min) was achieved with two devices, and single-needle dialysis was possible with one.
- The infection rate was low (1.7 episodes/1,000 days), with most devices remaining functional for over three years.
Impact:
- The LifeSite system provides an effective and durable alternative for hemodialysis vascular access when arteriovenous fistulas cannot be created.
- Successful long-term dialysis can be maintained, improving patient management and quality of life.
- The system demonstrates a favorable safety profile with manageable complications.